Testing antifungal vaccines in an animal model of invasive candidiasis and in human mucosal candidiasis

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

The following article will concentrate on the NDV-3 anti-Candida and Staphylococcus vaccine. The vaccine is composed of the N-terminal portion of the Candida albicans agglutinin-like sequence 3 protein (Als3p) and aluminum hydroxide as adjuvant. The vaccine conferred protection to mice against experimental vaginal, oral, and intravenous challenge with C. albicans. Due to the sequence and structural homology of the Als3p with Staphylococcus aureus surface proteins, the vaccine also protected against experimental skin and IV infection with S. aureus. The vaccine has reached the stage of human trials: phase 1 clinical studies have shown that the vaccine is safe and immunogenic. The latest brief conference abstract reports of vaccination in women suffering from recurrent vaginal candidiasis, indicating that the recurrence rates were lower in the women receiving the vaccine.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages343-353
Number of pages11
DOIs
StatePublished - 2017

Publication series

NameMethods in Molecular Biology
Volume1625
ISSN (Print)1064-3745

Keywords

  • Als3p
  • Candida albicans
  • NDV-3 vaccine
  • Staphylococcus aureus
  • Vaccine

Fingerprint

Dive into the research topics of 'Testing antifungal vaccines in an animal model of invasive candidiasis and in human mucosal candidiasis'. Together they form a unique fingerprint.

Cite this